Especially given the encouraging results of the phase 3 trial on the anti-IFN α/β receptor anifrolumab in patients with active SLE, such assays could guide the selection of patients likely to benefit from IFN-blocking treatment (9). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.